Terms: = Ovarian cancer AND PTPRC, LCA, 5788, ENSG00000081237, T200, GP180, B220, LY5, CD45 AND Treatment
25 results:
1. A Microfluidics Approach for ovarian cancer Immune Monitoring in an Outpatient Setting.
Libbrecht S; Vankerckhoven A; de Wijs K; Baert T; Thirion G; Vandenbrande K; Van Gorp T; Timmerman D; Coosemans A; Lagae L
Cells; 2023 Dec; 13(1):. PubMed ID: 38201211
[TBL] [Abstract] [Full Text] [Related]
2. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
3. Identification of two immune subtypes and four hub immune-related genes in ovarian cancer through multiple analysis.
Tang Q; Zhang H; Tang R
Medicine (Baltimore); 2023 Oct; 102(40):e35246. PubMed ID: 37800814
[TBL] [Abstract] [Full Text] [Related]
4. Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
5. Cellular and extracellular vaginal changes following murine ovarian removal.
McCracken JM; Calderon GA; Le QN; Faruqui NM; Balaji S; Hakim JCE
Physiol Rep; 2023 Aug; 11(15):e15762. PubMed ID: 37549960
[TBL] [Abstract] [Full Text] [Related]
6. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
7. Fusion Cell Markers in Circulating Tumor Cells from Patients with High-Grade ovarian Serous Carcinoma.
Ruano APC; Gadelha Guimarães AP; Braun AC; Flores BCTCP; Tariki MS; Abdallah EA; Torres JA; Nunes DN; Tirapelli B; de Lima VCC; Fanelli MF; Colombo PE; da Costa AABA; Alix-Panabières C; Chinen LTD
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499015
[TBL] [Abstract] [Full Text] [Related]
8. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
9. Glutamine deficiency promotes stemness and chemoresistance in tumor cells through DRP1-induced mitochondrial fragmentation.
Prasad P; Ghosh S; Roy SS
Cell Mol Life Sci; 2021 May; 78(10):4821-4845. PubMed ID: 33895866
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic and Clinical Value of Interleukin 6 and cd45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract] [Full Text] [Related]
11. BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells.
Payne KK; Mine JA; Biswas S; Chaurio RA; Perales-Puchalt A; Anadon CM; Costich TL; Harro CM; Walrath J; Ming Q; Tcyganov E; Buras AL; Rigolizzo KE; Mandal G; Lajoie J; Ophir M; Tchou J; Marchion D; Luca VC; Bobrowicz P; McLaughlin B; Eskiocak U; Schmidt M; Cubillos-Ruiz JR; Rodriguez PC; Gabrilovich DI; Conejo-Garcia JR
Science; 2020 Aug; 369(6506):942-949. PubMed ID: 32820120
[TBL] [Abstract] [Full Text] [Related]
12. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
[TBL] [Abstract] [Full Text] [Related]
13. Detection of Abundant Non-Haematopoietic Circulating cancer-Related Cells in Patients with Advanced Epithelial ovarian cancer.
Kumar J; Chudasama D; Roberts C; Kubista M; Sjöback R; Chatterjee J; Anikin V; Karteris E; Hall M
Cells; 2019 Jul; 8(7):. PubMed ID: 31319587
[No Abstract] [Full Text] [Related]
14. The human amniotic fluid mesenchymal stem cells therapy on, SKOV3, ovarian cancer cell line.
Gholizadeh-Ghaleh Aziz S; Fardyazar Z; Pashaiasl M
Mol Genet Genomic Med; 2019 Jul; 7(7):e00726. PubMed ID: 31111674
[TBL] [Abstract] [Full Text] [Related]
15. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence.
Astrup GL; Hofsø K; Bjordal K; Guren MG; Vistad I; Cooper B; Miaskowski C; Rustøen T
Acta Oncol; 2017 Mar; 56(3):462-470. PubMed ID: 28077018
[TBL] [Abstract] [Full Text] [Related]
16. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract] [Full Text] [Related]
17. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
[TBL] [Abstract] [Full Text] [Related]
18. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract] [Full Text] [Related]
19. Circulating endothelial progenitor cells in gynaecological cancer.
Kim YB; Chung YW; Bae HS; Lee JK; Lee NW; Lee KW; Song JY
J Int Med Res; 2013 Apr; 41(2):293-9. PubMed ID: 23569031
[TBL] [Abstract] [Full Text] [Related]
20. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis.
Waterman RS; Henkle SL; Betancourt AM
PLoS One; 2012; 7(9):e45590. PubMed ID: 23029122
[TBL] [Abstract] [Full Text] [Related]
[Next]
